Epivax, Inc.

PROVIDENCE, RI 02903

SBIR Award Summary

Total Number of Awards 25
Total Value of Awards $8.31MM
First Award Date 09/30/99
Most Recent Award Date 09/01/17

Key Personnel

Last Name Name Awards Contact
Martin William D Martin 2
De Groot Anne Searls De Groot 12
Degroot Anne Searls Degroot 11

25 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 09/01/17 - 08/31/18

ABSTRACT Significance: Graves? disease (GD), one of the most prevalent autoimmune diseases, is caused by stimulating autoantibodies (TSAb) to the Thyroid-Stimulating Hormone Receptor (TSHR), resulting in hyperthyroidism. Current methods for managing hyperthyroidism in GD target excess thyroid hormone secretion by ablation or removal of the thyro...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 07/01/17 - 06/30/18

? DESCRIPTION (provided by applicant): The avian-origin H7N9 influenza virus that emerged in humans in China in 2013 presents a unique challenge to vaccine development because it is poorly immunogenic. Neutralizing antibodies are not detected in acute-phase infection. Anti-H7 antibody responses are significantly delayed and exhibit low avidi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 07/01/16 - 06/30/17

? DESCRIPTION (provided by applicant): The avian-origin H7N9 influenza virus that emerged in humans in China in 2013 presents a unique challenge to vaccine development because it is poorly immunogenic. Neutralizing antibodies are not detected in acute-phase infection. Anti-H7 antibody responses are significantly delayed and exhibit low avidit...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 09/01/13 - 08/31/14

DESCRIPTION (provided by applicant): Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease Pompe disease is a lysosomal storage disorder caused by defects in the enzyme acid alpha-glucosidase (GAA) that leads to glycogen accumulation affecting heart and skeletal muscle. Enzyme-replacement therapy with recombinant human (rh)GAA saves...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 07/01/13 - 06/30/14

DESCRIPTION (provided by applicant): The goal of this new SBIR program is to produce a combined clotting Factor VIII replacement and immunomodulatory therapy that will provide FVIII-specific tolerance induction at therapeutic doses for Hemophilia A patients. Hemophiliacs with <1% functional FVIII are classified as severe and must receive regular...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 04/01/13 - 03/31/14

DESCRIPTION (provided by applicant): The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by optimizing the clinical delivery vehicle and treatment protocol, and by identifying correlates of efficacy in preparation for Phase 1 clinical tria...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 09/01/12 - 08/31/13

DESCRIPTION (provided by applicant): Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease Pompe disease is a lysosomal storage disorder caused by defects in the enzyme acid alpha-glucosidase (GAA) that leads to glycogen accumulation affecting heart and skeletal muscle. Enzyme-replacement therapy with recombinant human (rh)GAA saves...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 07/15/12 - 06/30/13

DESCRIPTION (provided by applicant): The goal of this new SBIR program is to produce a combined clotting Factor VIII replacement and immunomodulatory therapy that will provide FVIII-specific tolerance induction at therapeutic doses for Hemophilia A patients. Hemophiliacs with <1% functional FVIII are classified as severe and must receive regular...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 04/01/12 - 03/31/13

DESCRIPTION (provided by applicant): The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by optimizing the clinical delivery vehicle and treatment protocol, and by identifying correlates of efficacy in preparation for Phase 1 clinical tria...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-134
Budget: 09/10/10 - 06/30/11

DESCRIPTION (provided by applicant): Hemophilia A patients are prone to develop inhibitory immune responses to the very therapy they require: Factor VIII protein replacement. Up to 30% of all hemophiliacs and greater than 50% of severe hemophiliacs produce antibodies (inhibitors) in response to treatment. Immunogenicity to Factor VIII (FVIII) is...

Load More